About Us

Building the future

We develop a pipeline of urgently needed biosimilars for oncology and inflammatory diseases. Our biosimilars will widen the spectrum of therapeutic options with advantageous and affordable medications. We have implemented highly efficient structures for development and manufacturing, and we are progressing quickly on our way to the market. Our first product candidate, a biosimilar version of Neulasta® (pegfilgrastim) has already successfully demonstrated its quality on clinical level.

Scientific advances for more patients

Proven science, quality, safety and efficacy are the basis of our activities. We take into account the special requirements of all stakeholders, such as patients, physicians, pharmacists, healthcare service providers and business partners. That will allow us to reach more patients with our biosimilars and make valuable contributions to healthcare systems.

Member of a strong family

We are backed by our powerful parent company Infarco, which provides 50 years of experience in the development, manufacturing and commercialisation of pharmaceuticals. Infarco’s first subsidiary, Laboratorios Cinfa, has become a leader in the Spanish pharmaceutical market, offering a broad portfolio of quality drugs. Cinfa Biotech was founded to create a pipeline of biosimilars to address the growing need for affordable biologics therapies.

Made in Europe. Successful worldwide

With headquarters in Pamplona, Spain, and offices in Munich, Germany, Europe is the center of our activities. European standards, know-how and product quality will be the keys to Cinfa Biotech’s success in the global biosimilar markets.

A new way of thinking

Cinfa Biotech is different. A deep understanding of protein-based therapeutics and disease biology has enabled our team to define efficient biosimilar development programs, based on actual scientific, regulatory and healthcare marketplace considerations. Our team, supported by a strong parent company and a worldwide partner network, ensures that Cinfa Biotech’s development gains further momentum.